Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Paradiem LLC

Paradiem LLC grew its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 18.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 198,219 shares of the biopharmaceutical company’s stock after acquiring an additional 31,314 shares during the quarter. Paradiem LLC owned about 0.17% of Catalyst Pharmaceuticals worth $3,332,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in CPRX. Russell Investments Group Ltd. raised its position in shares of Catalyst Pharmaceuticals by 5.5% during the fourth quarter. Russell Investments Group Ltd. now owns 191,881 shares of the biopharmaceutical company’s stock worth $3,226,000 after purchasing an additional 10,013 shares during the period. Linden Thomas Advisory Services LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $186,000. Parkside Financial Bank & Trust acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $31,000. Louisiana State Employees Retirement System acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $842,000. Finally, Cerity Partners LLC raised its position in shares of Catalyst Pharmaceuticals by 11.5% during the fourth quarter. Cerity Partners LLC now owns 17,231 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 1,780 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Oppenheimer reissued an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Tuesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $34.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 22nd. StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Finally, Bank of America began coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a “buy” rating and a $23.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $26.43.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 25,000 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the sale, the director now owns 348,874 shares in the company, valued at approximately $5,470,344.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 12.10% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Trading Up 1.4 %

NASDAQ CPRX traded up $0.21 on Friday, reaching $14.89. The stock had a trading volume of 772,457 shares, compared to its average volume of 1,275,823. The business has a 50 day moving average price of $15.54 and a 200 day moving average price of $14.63. Catalyst Pharmaceuticals, Inc. has a 1 year low of $11.09 and a 1 year high of $17.76. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 24.41, a P/E/G ratio of 0.82 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. On average, analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.